Acquisitions16 Apr 2025, 02:31 pm
Dr. Reddy's Among Potential Acquirers of Sanofi's Star Insulin Brand
AI Summary
In a recent development, Sanofi India has initiated the process of selling its flagship insulin brand, Lantus. According to a news article in The Economic Times, Dr. Reddy's Laboratories Limited is one of the potential acquirers. However, Dr. Reddy's has refrained from commenting on market speculations and stated that there is no material event or information requiring disclosure as of now. The company is committed to complying with Regulation 30 of the SEBI Listing Regulations, promptly disclosing any material event or information.
Key Highlights
- Sanofi India initiates sale process for its flagship insulin brand, Lantus
- Dr. Reddy's Laboratories Limited reported as a potential acquirer
- Dr. Reddy's refrains from commenting on market speculations
- No material event or information requiring disclosure at present
- Company committed to complying with Regulation 30 of SEBI Listing Regulations